![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, November 20, 2014 1:51:05 PM
Microcap Daily
Aethlon Medical, Inc. (OTCMKTS:AEMD) Successfully Beating Ebola 0
BY BRYAN CROWE ON NOVEMBER 20, 2014 EMERGING MARKETS, MICRO CAP INSIDER
Aethlon Medical, Inc. (OTCMKTS:AEMD) is quickly turning into one of the most exciting stories in small caps. Riding on a wave of Ebola penny stock euphoria this one is moving up off its base at a dime.
The excitement on AEMD is all about their bio-filtration device, the Aethlon Hemopurifier® which they have successfully used to treat a critically-ill Ebola-infected patient in Frankfurt, Germany.
The patient was a Ugandan Doctor, who was infected with Ebola in Sierra Leone where he was treating Ebola patients. At the time of treatment, which occurred at Frankfurt University Hospital, the patient was unconscious and suffering from multiple organ failure.
According to recent data which Aethlon presented at the American Society of Nephrology (ASN) Annual Meeting ” 242 million Ebola viruses were captured within the Aethlon Hemopurifier® during treatment, a number verified by a post-treatment elution protocol. The patient is no longer infected with Ebola virus and is expected to make a full recovery.
Since Aethlon completed the first treatment in mid-October the stock has exploded more than 4 fold off its base at a dime and has quickly become one of the top 3 most traded stocks on the entire OTCBB market.
Aethlon Medical, Inc. (OTCMKTS:AEMD) is a San Diego, California based Medical Device Company focused on creating innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions.
At the core of Aethlon is their Adaptive Dialysis-Like Affinity Platform Technology System (ADAPT™) a medical device platform that converges single or multiple affinity drug agents with advanced plasma membrane technology to create therapeutic filtration devices that selectively remove harmful particles from the entire circulatory system without loss of essential blood components.
They developed the Aethlon Hemopurifier® a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals.
Back in June of this year the FDA approved an Investigational Device Exemption (IDE) that allowed Aethlon to initiate human feasibility studies of the Aethlon Hemopurifier® in the United States.
AEMD currently averages just under $500,000 a quarter in revenues that are derived from a DARPA Government contract that was awarded to the Company back in September 2011. Under the terms of the contract Aethlon is developing a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that often results in the death of combat-injured soldiers. The award from DARPA was a fixed-price contract with potential total payments to us of $6,794,389 over the course of five years.
On November 19 Aethlon said will provide Hemopurifier® therapy under FDA expanded access “emergency use” provisions to support requests from qualified physicians and institutes that may seek to treat Ebola virus infection in the United States.
Conclusion: Over the past few weeks AEMD has transformed from unknown and illiquid at a dime to one of the top most traded stocks on the entire OTCBB nearing $0.50 per share. The parabolic move comes on massive investor interest as Aethlon successfully treats a critically-ill Ebola-infected patient with the Aethlon Hemopurifier®.
Positive news continues to flow from the Company as they expand studies for the device in the US under a new FDA Investigational Device Exemption (IDE).
The Ebola virus continues to rage in West Africa with 14,000 reported cases as of November 11 and 5,177 dead in six countries including Liberia, Guinea, Sierra Leone, Nigeria, the United States and Mali.
Currently trading at a $115 million market valuation AEMD has captured the imaginations of small cap investors and is quickly building a loyal shareholder base that swears this one goes higher.
Recent AEMD News
- Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update • PR Newswire (US) • 06/27/2024 08:15:00 PM
- Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024 • PR Newswire (US) • 06/21/2024 12:01:00 PM
- Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial • PR Newswire (US) • 06/18/2024 12:01:00 PM
- Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies • PR Newswire (US) • 06/03/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 05:24:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:05:28 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/17/2024 04:15:21 AM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/16/2024 08:05:23 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 05/15/2024 01:27:15 PM
- Aethlon Medical Announces Pricing of $4.7 Million Public Offering • PR Newswire (US) • 05/15/2024 01:15:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/13/2024 09:30:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 12:01:40 PM
- Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma • PR Newswire (US) • 05/10/2024 12:01:00 PM
- Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices • PR Newswire (US) • 02/21/2024 01:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 10:15:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:15:41 PM
- Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update • PR Newswire (US) • 02/14/2024 09:15:00 PM
- Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024 • PR Newswire (US) • 02/07/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:06:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:04:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:02:52 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/22/2023 09:01:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 12:49:31 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM